Clinical Trial

DAOIB for the Treatment of Brain Fog

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 19, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a 24-week open trial. We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB treatment will be beneficial in improving the cognitive function, mood symptoms, global functioning and quality of life in long-COVID patients with cognitive impairments.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-02-28; most recent amendment 2026-03-18.
Trial Details
NCT Number NCT05764538
Lead Sponsor Chang Gung Memorial Hospital
Conditions Long COVID
Enrollment 40 participants
Start Date 2023-02-27
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-19